← 返回

“工程化巨噬细胞在乳腺癌中的应用:连接靶向治疗与先进药物递送”的勘误 [Int. Immunopharmacol. 163 (2025) 115237]

英文原题:Corrigendum to "Engineered macrophages in breast cancer: bridging targeted therapy and advanced drug delivery" [Int. Immunopharmacol. 163 (2025) 115237].

查看英文原题

Corrigendum to "Engineered macrophages in breast cancer: bridging targeted therapy and advanced drug delivery" [Int. Immunopharmacol. 163 (2025) 115237].

PubMed 2025/07/25(内容时间) Int Immunopharmacol Q1 · IF 5.6(JCR 2025)

分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。

摘要

这条来源本身就没有摘要(PubMed 未提供),不是「还没翻译」。可以点最下面的「在 PubMed 查看」打开原文献页面。

论文信息

作者
Qian D、Mu Y、Jiang Z、Liu H、Zhu L、Yang Z、Wu C、He C
第一作者单位
Central Laboratory, Changshu Hospital Affiliated to Soochow University, Changshu No.1 People's Hospital, Changshu 215500, China; General Surgery, Cancer Center, Department of Breast Surgery, Zhejiang Provincial People's Hospital (Affiliated People's Hospital), Hangzhou Medical College, Hangzhou 310014, China.China
通讯作者单位
General Surgery, Cancer Center, Department of Breast Surgery, Zhejiang Provincial People's Hospital (Affiliated People's Hospital), Hangzhou Medical College, Hangzhou 310014, China. Electronic address: mxlmail@126.com.China
文献类型
勘误
期刊
International immunopharmacology2025 Sep 23
原文标识
PubMed 40713371 · DOI 10.1016/j.intimp.2025.115279